Skip to main content
Premium Trial:

Request an Annual Quote

Emerald BioStructures, UCB Extend Deal for Drug Target Identification

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The three-year extension provides the company with research funding, it said. The Bainbridge Island, Wash.-based firm also is eligible for milestone payments and royalties on future drug product revenues.

Additional financial and other details of the deal were not disclosed.

The collaboration between Emerald and UCB, a global biopharmaceutical firm based in Brussels, originally dates to 2009. Earlier this year, the firms said they had achieved a second milestone in their partnership and expanded the alliance.

Emerald is contributing its expertise in high-throughput crystallography and ligand characterization "to provide fragment screening and structural biology support for UCB's severe diseases discovery programs," it said.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.